Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Conference reports
Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetic targets for efavirenz might be too high
24 March 2014. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study
24 March 2014. Related: Conference reports, Side effects.
NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs
24 March 2014. Related: Conference reports, Treatment strategies, Drug resistance.
HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART
24 March 2014. Related: Conference reports, Pregnancy.
Lower newborn bone mineral content with maternal tenofovir use
24 March 2014. Related: Conference reports, Pregnancy.
Paediatric pipeline: CROI 2014 update on new antiretrovirals for children
24 March 2014. Related: Conference reports, Paediatric care.
Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis
24 March 2014. Related: Conference reports, Paediatric care.
Xpert TB test has important advantages but does not reduce morbidity
24 March 2014. Related: Conference reports, TB coinfection.
Reports of a second baby possibly cured of HIV: uncertainty remains
24 March 2014. Related: Conference reports, Cure-related research, Basic science and immunology.
Updates on SB728-T, a CCR5-targeting gene therapy
24 March 2014. Related: Conference reports, Cure-related research, Basic science and immunology.
4th International Workshop on HIV & Women, 13-14 January 2014, Washington
1 February 2014. Related: Conference reports.
Women, HIV research and antiretrovirals
1 February 2014. Related: Conference reports, Antiretrovirals, Women's health, Cure-related research.
Improved virological outcomes for women starting efavirenz-based first-line regimens in South Africa
1 February 2014. Related: Conference reports, Women's health.
High rates of pregnancy in HIV positive women in Zambia and South Africa
1 February 2014. Related: Conference reports, Women's health, Pregnancy.
Contraceptive choices among a Canadian cohort of HIV positive women
1 February 2014. Related: Conference reports, Women's health.
Bone disease and older HIV positive women
1 February 2014. Related: Conference reports, Women's health.
Lower immune response to the qHPV vaccine in HIV positive girls
1 February 2014. Related: Conference reports, Women's health, Paediatric care.
HIV exposed vs unexposed babies have lower gestational age and birth weight in Danish study
1 February 2014. Related: Conference reports, Pregnancy, Paediatric care.
Outcomes in infants exposed to lopinavir/ritonavir in utero
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
17th International Conference on AIDS and STIs in Africa (ICASA), 7-11 December 2013, Cape Town
1 February 2014. Related: Conference reports.
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
6th International Workshop on HIV Persistence During Therapy, 3-6 December 2013, Miami, USA
1 February 2014. Related: Conference reports.
Report from the 6th Workshop on HIV Persistence
1 February 2014. Related: Conference reports, Cure-related research.
44th Union World Conference on Lung Health, 30 October – 3 November 2013, Paris
1 December 2013. Related: Conference reports.
Preventing and treating TB in children – more baby steps
1 December 2013. Related: Conference reports, Paediatric care, PK and drug interactions, TB coinfection.
14th European AIDS Conference (EACS), 16-19 October 2013, Brussels
1 December 2013. Related: Conference reports.
Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study
1 December 2013. Related: Conference reports, Antiretrovirals.
GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections
1 December 2013. Related: Conference reports, Antiretrovirals.
Cenicriviroc: 48 week results compared to efavirenz
1 December 2013. Related: Conference reports, Antiretrovirals.
Approaches to once-daily raltegravir: new formulation likely to require food
1 December 2013. Related: Conference reports, Antiretrovirals.
DSMB stops boosted atazanavir monotherapy study due to virological failure
1 December 2013. Related: Conference reports, Antiretrovirals.
Recreational drug use is common in HIV positive gay men and is extensive in a significant minority
1 December 2013. Related: Conference reports, Antiretrovirals.
Caution against prolonged use of bisphosphonates in patients with mild-moderate fracture risk
1 December 2013. Related: Conference reports, Coinfections and complications.
Osteoporosis triples risk of later fracture in 1000-person US HIV group
1 December 2013. Related: Conference reports, Coinfections and complications.
Bone turnover marker changes early in ART predict bone loss after 96 week
1 December 2013. Related: Conference reports, Coinfections and complications.
Low HDL cholesterol is main lipid abnormality in HIV+/HIV- comparison
1 December 2013. Related: Conference reports, Weight, diabetes, metabolic complications.
Classic risk factors, but not HIV, linked to arterial stiffness in middle-aged
1 December 2013. Related: Conference reports, Coinfections and complications.
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 10-13 September 2013, Denver
1 October 2013. Related: Conference reports.
Raltegravir safe and effective in pregnancy in small French study
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Good safety profile with long-acting integrase inhibitor GSK744
1 October 2013. Related: Conference reports, Antiretrovirals.
TAF comparable to TDF in once-daily pill for ART-naive: 48-week results
1 October 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial
1 October 2013. Related: Conference reports, Antiretrovirals.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
1 October 2013. Related: Conference reports.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
PrEP gives little extra benefit in attempted conception if male partner is on ART
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 30 June – 3 July 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.
WHO 2013 guidelines: what about the missing formulations?
25 July 2013. Related: Conference reports, Treatment access, Paediatric care, Guidelines.
WHO 2013 guidelines: when the risk:benefit may not favour starting at CD4 count of 500
25 July 2013. Related: Conference reports, Guidelines.
Efavirenz at 400 mg compared to standard 600 mg dose has similar efficacy with fewer side effects
25 July 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir update: drug resistance in people who are treatment-naive and -experienced
25 July 2013. Related: Conference reports, Antiretrovirals, Drug resistance.
Elvitegravir/cobicisat/tenofovir/FTC: Stribild studies at IAS 2013
25 July 2013. Related: Conference reports, Antiretrovirals.
Non-standard combinations: NRTI-sparing combinations
25 July 2013. Related: Conference reports, Antiretrovirals.
ARVs and bone health: the role of NRTIs in second-line therapy
25 July 2013. Related: Conference reports, Side effects.
No viral load rebound off-ART following stem cell transplant: two “cure” cases using reduced intensity conditioning chemotherapy and CCR5 d-32 negative donors
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
HIV cure research: further capsules at IAS 2013
25 July 2013. Related: Conference reports, Cure-related research, Basic science and immunology.
Partner-dependent immune differences may protect against HIV infection
25 July 2013. Related: Conference reports, HIV prevention and transmission.
Pipeline oral HCV drugs and generic global access to DAAs: the need to mirror ARV programmes
25 July 2013. Related: Conference reports, Treatment access, Hepatitis coinfection.
5th International Workshop on HIV Pediatrics, 28-29 June 2013, Kuala Lumpur
25 July 2013. Related: Conference reports.
Vertical transmission continues to decline in UK and Ireland
25 July 2013. Related: Conference reports, Pregnancy.
Decline in late preterm delivery with vaginal birth in Europe
25 July 2013. Related: Conference reports, Pregnancy.
High loss to follow up among asymptomatic women starting ART in pregnancy in Option B+
25 July 2013. Related: Conference reports, Antiretrovirals, Pregnancy.